A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothée Sémiond, Disa Yu, Paúl Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau
Abstract
Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.